araag2/HINT huggingface dataset:
Clinical trial NCT02598310 (phase 2, status: terminated)
Conditions: breast cancer, estrogen receptor negative neoplasm, her-2 positive breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: nab-paclitaxel, trastuzumab
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed invasive breast cancer

          2. Tumor size of 3cm or less and N0

          3. Hormone receptors have been identified as negative

          4. HER2 positive confirmed by IHC 3+ or FISH+

          5. LVEF > 50% by echocardiogram or MUGA

          6. Adequate EKG

          7. No prior treatment for breast cancer

          8. PS 0-1

          9. Required baseline laboratory data WBC > 4,000/mm3 and Neut > 2,000/mm3 PLT >
             100,000/mm3 Hb > 9.0g/dl AST and ALT < ULNx2.5 T-Bil < 1.5mg/dl Serum creatinin <
             1.5mg/dl

         10. Written informed consent

        Exclusion Criteria:

          1. With history of hypersensitivity reaction for important drug in this study

          2. With history of invasive breast cancer

          3. Bilateral invasive breast cancer

          4. Patients with medical conditions that renders them intolerant to primary chemotherapy
             and related treatment, including infection, diarrhea, intestinal paralysis, severe
             Diabetes Mellitus

          5. Positive for HBs antigen or HCV antibody

          6. With history of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction, poorly controlled hypertension

          7. With severe edema

          8. With severe peripheral neuropathy

          9. With severe psychiatric disorder

         10. Pregnant or nursing women

         11. The case that is judged to be unsuitable for this study by physician
Clinical trial NCT02603809 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: aprocitentan 5 mg, aprocitentan 10 mg, aprocitentan 25 mg, aprocitentan 50 mg, lisinopril 20 mg, placebo
SMILES: CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  No contra-indication to stop (according to label) anti-hypertensive treatment(s) at
             screening

          -  Mild-to-moderate essential hypertension with or without ongoing anti-hypertensive
             treatment(s):

             -- Mean (of 5 measurements) sitting diastolic blood pressure (SiDBP) ≥ 90 to < 110
             mmHg measured by office blood pressure measurements (OBPM).

          -  Women of childbearing potential must have a negative pregnancy test and use of
             reliable methods of contraception

        Exclusion Criteria:

          -  Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP;
             measured by OBPM) ≥ 180/110 mmHg, respectively.

          -  Secondary hypertension

          -  Known hypertensive retinopathy greater than Keith-Wagener Grade 2

          -  Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary
             artery bypass graft within 12 months prior to randomization

          -  Unstable angina within 6 months prior to randomization

          -  Heart failure New York Heart Association class III and IV

          -  Valvular defects (such as severe aortic or mitral valve disease) and/or
             hemodynamically relevant rhythm disturbances

          -  Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident
             within 6 months prior to randomization.

          -  Subjects working night shifts

          -  Body mass index < 20 kg/m2 or > 40 kg/m2

          -  Treatment with any medication which may affect BP (e.g., treatment of psychiatric
             diseases, ophthalmic preparations)

          -  Treatment with strong cytochrome P450 3A4 (CYP3A4) isoenzyme inhibitors or inducers

          -  Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1
             month prior to Screening (Visit 1)

          -  Treatment with another investigational treatment within 1 month prior to Screening
             (Visit 1)

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
Clinical trial NCT02608697 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: cat-2054, placebo, atorvastatin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Between 18 and 74 years at Screening

          -  Hypercholesterolemia (LDL-C ≥ 70 mg/dL and < 190 mg/dL) plus a stable dose of statin
             for at least 4 weeks prior to Screening

          -  Satisfies one of the following:

               1. Female patients of childbearing potential must have used appropriate and highly
                  effective contraception (a regimen which results in a failure rate of <1% per
                  year) with their partners for 4 weeks prior to Screening, and remain compliant
                  during the treatment phase and until 4 weeks after the last dose of
                  investigational product

               2. Male patients must use an acceptable and highly effective contraceptive method
                  during the treatment phase and until 4 weeks after the last dose of
                  investigational product

          -  Body mass index (BMI) ≤45 kg/m2

        Exclusion Criteria:

          -  History of any major cardiovascular event (stroke, TIA, MI, PTCI, CABG,
             hospitalization due to heart failure) within 6 months of Screening

          -  Type I diabetes mellitus or use of insulin

          -  Active peptic ulcer disease or a history of muscle disease or myopathy
Clinical trial NCT02609334 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: crd007
SMILES: CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18 and <50 years

          -  Diagnosis of asthma

        Exclusion Criteria:

          -  Clinical significant comorbidities

          -  Lower respiratory tract infection <6 weeks prior to Visit 1

          -  Others, as specified in the protocol
Clinical trial NCT02610140 (phase 2, status: completed)
Conditions: mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: anetumab ravtansine (bay94-9343), vinorelbine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histological documentation of malignant pleural mesothelioma (MPM) overexpressing
             mesothelin

          -  Unresectable locally advanced or metastatic MPM after locally confirmed progression on
             1st line treatment with platinum in combination with pemetrexed.

          -  Patients must have measurable disease

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

          -  Life expectancy of at least 3 months.

          -  Adequate bone marrow, liver and renal function

          -  Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN)
             according to local institution ranges of normality.

        Exclusion Criteria:

          -  More than 1 previous systemic anti-cancer therapy line

          -  Patients with corneal epitheliopathy or any eye disorder that may predispose the
             patients to this condition at the discretion of the investigator in consultation with
             the ophthalmologist.

          -  Brain metastases, meningeal tumours or other metastases in the central nervous system

          -  Evidence of history of bleeding diathesis.

          -  Ongoing or active infection (bacterial, fungal, or viral) of National Cancer
             Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03
             Grade > 2.

          -  Pre-existing cardiac conditions
Clinical trial NCT02612285 (phase 2, status: terminated)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: snx-5422
SMILES: CC1(C)CC2=C(C(=NN2C2=CC(N[C@H]3CC[C@@H](CC3)OC(=O)CN)=C(C=C2)C(N)=O)C(F)(F)F)C(=O)C1
Reason stopped: 
    recruitment very slow - study could not be enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed solid or hematological TP53 null type cancer.

          -  No more than 4 prior lines of systemic anti-cancer therapy.

          -  Males or non-pregnant, non-breastfeeding females 18 years-of-age or older.

          -  Karnofsky performance score 60

          -  Life expectancy of at least 3 months.

          -  Adequate baseline laboratory assessments

          -  Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1 with the
             exception of alopecia.

        Exclusion Criteria:

          -  Treatment with an investigational agent within 30 days prior to the first dose of
             SNX-5422 or planning to receive an investigational agent during the study.

          -  Treatment with other anticancer drugs within 28 days or 5 half-lives of anticancer
             therapy (whichever is shorter) is prohibited from 30 days prior to the first dose of
             SNX-5422 and throughout the study.

          -  Radiation treatment within 2 weeks.

          -  The need for treatment with medications with clinically relevant metabolism by the
             cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of
             SNX-5422 (Appendix B).

          -  Appropriately corrected screening ECG QTc interval 470 msec for females, 450 msec for
             males.

          -  Currently receiving medications known to cause QT prolongation AND corrected QTc of
             450 msec for females, 430 msec for males.

          -  Patients with chronic diarrhea of grade 2 or greater despite maximal medical
             management.

          -  Gastrointestinal diseases or conditions that could affect drug absorption, including
             gastric bypass.

          -  Gastrointestinal diseases that could alter the assessment of safety, including
             irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic
             coloproctitis.

          -  History of documented adrenal dysfunction not due to malignancy.

          -  Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).

          -  History of chronic liver disease.

          -  Active hepatitis A or B.

          -  Current alcohol dependence or drug abuse.

          -  Clinically significant glaucoma, retinitis pigmentosa, or macular degeneration.

          -  Other serious concurrent illness or medical condition.
Clinical trial NCT02612610 (phase 2, status: completed)
Conditions: refractory chronic cough
ICD codes: D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, D46.22
Drugs: gefapixant, placebo (for gefapixant)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women and Men between 18 and 80 years of age inclusive

          -  Have refractory chronic cough

          -  Women of child-bearing potential must use 2 forms of acceptable birth control - Have
             provided written informed consent.

          -  Are willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Current smoker

          -  Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio <60%

          -  History of upper or lower respiratory tract infection or recent significant change in
             pulmonary status within 4 weeks of the Baseline Visit

          -  History of opioid use within 1 week of the Baseline Visit

          -  Body mass index (BMI) <18 kg/m^2 or ≥ 40 kg/m^2

          -  History of concurrent malignancy or recurrence of malignancy within 2 years prior to
             Screening (not including subjects with <3 excised basal cell carcinomas)

          -  Screening systolic blood pressure (SBP) >160 mm Hg or a diastolic blood pressure (DBP)
             >90 mm Hg

          -  Clinically significant abnormal electrocardiogram (ECG) at Screening

          -  Significantly abnormal laboratory tests at Screening

          -  Pregnant or Breastfeeding

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with trial participation or
             investigational product administration or may interfere with the interpretation of
             trial results and, in the judgment of the Investigator or Sponsor, would make the
             participant inappropriate for entry into this trial
Clinical trial NCT02617667 (phase 2, status: completed)
Conditions: dry eye syndromes
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: cyclosporine a, placebo
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent Form and HIPAA (Health Insurance Portability and
             Accountability Act ) document

          -  Patient-reported history of dry eye in both eyes

          -  Current use of over-the-counter and/or prescription eye drops for dry eye symptoms

          -  Ability and willingness to follow instructions, including participation in all study
             assessments and visits

        Exclusion Criteria:

          -  Women who are pregnant, nursing or planning a pregnancy

          -  Unwillingness to submit a blood pregnancy test at screening and at the last visit (or
             early termination visit) if of childbearing potential, or unwillingness to use
             acceptable means of birth control

          -  Clinically significant slit-lamp findings or abnormal lid anatomy at screening

          -  DED secondary to scarring or ocular or periocular malignancy

          -  History of herpetic keratitis

          -  Active ocular allergies or ocular allergies that are expected to be active during the
             study period

          -  Ongoing ocular or systemic infection at screening or baseline

          -  Wear of contact lenses within 3 months prior to screening or anticipated use of
             contact lenses during the study

          -  History of no response to previous topical Cyclosporine A and/or use of topical
             Cyclosporine A within 6 months prior to screening

          -  Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have any
             planned ocular and/or lid surgeries over the study period

          -  Presence of an uncontrolled systemic disease

          -  Presence of a known allergy and/or sensitivity to the study drug or its components
Clinical trial NCT02623738 (phase 2/phase 3, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: placebo ophthalmic solution, de-117 ophthalmic solution low, de-117 ophthalmic solution high, latanoprost ophthalmic solution 0.005%
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary open angle glaucoma or ocular hypertension

        Exclusion Criteria:

          -  Patients at risk of progression of visual field loss

          -  Patients with severe visual field defect

          -  Patients with any diseases that preclude participation in this study for safety
             reasons
Clinical trial NCT02626572 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: s47445 5mg, s47445 15mg, s47445 50mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Out-patients

          -  Able to perform neuropsychological tests

          -  Have a responsible informant

          -  DSM-IV-TR criteria for Dementia of the Alzheimer's Disease Type

          -  Mini mental State Examination (MMSE) = 15-24 both inclusive

          -  National Institute of Mental Health (NIMH) provisional criteria for depression in AD
             (NIMH-dAD)

          -  Cornell Scale for Depression in Dementia total score > or = 8

          -  Patients who have never been treated with AD treatments or patients who have stopped
             AD treatment whatever the reason

          -  Patients either not currently treated with an antidepressant or patients being treated
             with an antidepressant at the recommended dose for at least 8 weeks without clinical
             efficacy, who can stop this treatment according to the investigator's opinion.

        Exclusion Criteria:

          -  Patients not able to read or write

          -  Patients having participated in a study testing disease modifying therapy for AD, or
             in another study with administration of investigational drug or device within the
             previous 3 months prior to selection visit

          -  Depressive symptoms that, in investigator's judgment, are clearly due to a medical
             condition other than AD, or are a direct result of non-mood related dementia symptoms

          -  History of epilepsy or solitary seizure

          -  Medical history of Major Depressive Disorder more than 3 years before onset of the
             disease, treated with antidepressive drugs or electroconvulsive therapy

          -  Severe or unstable disease of any type that could interfere with safety and efficacy
             assessments

          -  Alcohol abuse or drug abuse or addiction, as judged by the clinician (excluding
             nicotine)

          -  Clinically relevant lactose intolerance

          -  Antidepressant treatment not stopped for at least 3 weeks before inclusion

          -  Significant worsening of depressive symptoms or high suicidal risk according to
             investigator's judgment

          -  For optional extension phase: medically instable Chronic Obstructive Pulmonary Disease
             and asthma, known hypersensitivity to donepezil hydrochloride or piperidine
             derivatives
Clinical trial NCT02626754 (phase 2, status: terminated)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sunitinib malate
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Reason stopped: 
    in most sites had difficult to recruitting subjects.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced renal cell carcinoma with histology confirmation

          -  Grade III/IV AEs happen during first cycle of sunitinib 50mg/day 4 weeks on followed
             by 2 weeks of rest

          -  ECOG performance status 0 or 1

          -  Appropriate vital organ functions

        Exclusion Criteria:

          -  Prior systemic treatment of mRCC

          -  Patients treated with any neoadjuvant or adjuvant systemic therapy

          -  Major surgery <4 weeks or radiation therapy <2 weeks of starting the study treatment.
             Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is
             at least one measurable lesion that has not been irradiated

          -  Pregnant

          -  Allergic history to sunitinib
Clinical trial NCT02627573 (phase 2, status: terminated)
Conditions: leukemia, chronic myeloid, myelodysplastic syndromes, leukemia, myeloid, chronic, atypical, bcr-abl negative
ICD codes: D46.9, D46.C, D46.Z
Drugs: busulfan, fludarabine monophosphate, tacrolimus, mycophenolate mofetil, cyclophosphamide, thymoglobulin
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Reason stopped: 
    poor recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have an indication for allogeneic hematopoietic stem cell
             transplantation

          -  Diagnosis: Chronic myeloid leukemia Myelodysplastic Syndromes Myeloprolipherative
             neoplsm unclassified Atypical chronic myelogenous leukemia

          -  Signed informed consent

          -  Patients with 10/10 HLA-matched unrelated donor available. The donor and recipient
             must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and
             HLA-DQB1. Mismatches in these loci are not allowed.

          -  Peripheral blood stem cells as graft source

          -  No second tumors

          -  No prior history of Thymoglobulin exposure or no history of anaphylactic shock after
             Thymoglobulin administration

          -  No severe concurrent illness

        Exclusion Criteria:

          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction <50%

          -  Moderate or severe decrease in pulmonary function, FEV1 <70% or DLCO<70% of predicted

          -  Respiratory distress >grade I

          -  Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper
             normal limits, creatinine >2 upper normal limits

          -  Creatinine clearance < 60 mL/min

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index <30%

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent